LaFrance Norman D. 4
4 · Molecular Insight Pharmaceuticals, Inc. · Filed May 29, 2009
Insider Transaction Report
Form 4
LaFrance Norman D.
Sr. VP Clinical Dev and CMO
Transactions
- Sale
Common Stock
2009-05-28$3.76/sh−6,093$22,910→ 16,657 total
Footnotes (1)
- [F1]Shares were sold through broker to cover withholding tax liabilities on the vesting of shares of restricted stock.